geniposide has been researched along with Carcinoma, Hepatocellular in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Chen, F; Feng, Y; Guo, W; Lao, L; Man, K; Tan, HY; Tsao, SW; Wang, N; Zhang, C; Zhong, Z | 1 |
Cheung, F; Feng, Y; Hong, M; Lao, L; Nagamatsu, T; Tan, HY; Wang, N | 1 |
2 other study(ies) available for geniposide and Carcinoma, Hepatocellular
Article | Year |
---|---|
Direct inhibition of the TLR4/MyD88 pathway by geniposide suppresses HIF-1α-independent VEGF expression and angiogenesis in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Endothelial Cells; Hypoxia-Inducible Factor 1, alpha Subunit; Iridoids; Liver Neoplasms; Mice; Myeloid Differentiation Factor 88; Neovascularization, Pathologic; Toll-Like Receptor 4; Vascular Endothelial Growth Factor A | 2020 |
Inhibition of eukaryotic elongation factor-2 confers to tumor suppression by a herbal formulation Huanglian-Jiedu decoction in human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Berberine; Carcinoma, Hepatocellular; Cell Line, Tumor; Drugs, Chinese Herbal; Elongation Factor 2 Kinase; Female; Flavonoids; Humans; Iridoids; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Phytotherapy; Xenograft Model Antitumor Assays | 2015 |